Format

Send to

Choose Destination
Breast. 2011 Aug;20(4):319-23. doi: 10.1016/j.breast.2011.02.014. Epub 2011 Mar 11.

Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer.

Author information

1
Medical Senology Research Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. silvia.dellapasqua@ieo.it

Abstract

AIM:

To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophosphamide as primary systemic treatment in locally advanced breast cancer.

PATIENTS AND METHODS:

The activity and safety of intravenous pegylated liposomal doxorubicin 20 mg sqm(-1) biweekly for eight courses in combination with metronomic cyclophosphamide 50 mg day(-1) orally were evaluated in 29 patients with locally advanced breast cancer who were not suitable to receive a standard chemotherapy due to age or co-morbidities or who asked for a regimen with low incidence of toxic effects irrespective of age.

RESULTS:

The rate of breast-conserving surgery was 44.8%. Eighteen patients (62.1%) achieved a partial response (including one pathological complete response), 10 (34.5%) a stable disease and one patient experienced a progressive disease. Treatment was well tolerated, with no grade 4 toxicities, and with grade 3 skin toxicity in three patients and hand-foot syndrome in four patients.

CONCLUSION:

The regimen was well tolerated but with limited activity in the preoperative setting. Other options (e.g., endocrine therapy in estrogen receptor -positive disease) should be considered in locally advanced breast cancer patients who are not suitable to receive a standard chemotherapy.

PMID:
21397505
DOI:
10.1016/j.breast.2011.02.014
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Archivio Istituzionale della Ricerca Unimi
Loading ...
Support Center